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Abstract 
Copy number variants (CNVs) have been strongly implicated in the genetic etiology of 
schizophrenia (SCZ). However, genome-wide investigation of the contribution of CNV to 
risk has been hampered by limited sample sizes. We sought to address this obstacle by 
applying a centralized analysis pipeline to a SCZ cohort of 21,094 cases and 20,227 
controls. A global enrichment of CNV burden was observed in cases (OR=1.11, P=5.7x10-
15), which persisted after excluding loci implicated in previous studies (OR=1.07, P=1.7 
x10-6). CNV burden was enriched for genes associated with synaptic function (OR = 1.68, 
P = 2.8 x10-11) and neurobehavioral phenotypes in mouse (OR = 1.18, P= 7.3 x10-5). 
Genome-wide significant evidence was obtained for eight loci, including 1q21.1, 2p16.3 
(NRXN1), 3q29, 7q11.2, 15q13.3, distal 16p11.2, proximal 16p11.2 and 22q11.2. 
Suggestive support was found for eight additional candidate susceptibility and protective 
loci, which consisted predominantly of CNVs mediated by non-allelic homologous 
recombination.  
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Introduction 
Studies of genomic copy number variation (CNV) have established a role for rare 
genetic variants in the etiology of SCZ 1. There are three lines of evidence that CNVs 
contribute to risk for SCZ: genome-wide enrichment of rare deletions and duplications in 
SCZ cases relative to controls 2,3 , a higher rate of de novo CNVs in cases relative to 
controls4-6, and association evidence implicating a small number of specific loci 
(Supplementary Table 1). All CNVs that have been implicated in SCZ are rare in the 
population, but confer significant risk (odds ratios 2-60).  
To date, CNVs associated with SCZ have largely emerged from mergers of 
summary data for specific candidate loci 7-9; yet even the largest genome-wide scans 
(sample sizes typically <10,000) remain under-powered to robustly confirm genetic 
association for the majority of pathogenic CNVs reported so far, particularly for those 
with low frequencies (<0.5% in cases) or intermediate effect sizes (odds ratios 2-10). It is 
important to address the low power of CNV studies with larger samples given that this 
type of mutation has already proven useful for highlighting some aspects of SCZ related 
biology 6,10-13.  
The limited statistical power provided by small samples is a significant obstacle in 
studies of rare and common genetic variation. In response, global collaborations have 
been formed in order to attain large sample sizes, as exemplified by a study by the 
Schizophrenia Working Group of the Psychiatric Genomics Consortium (PGC) which 
identified 108 independent schizophrenia associated loci 14. Recognizing the need for 
similarly large samples in studies of CNVs for psychiatric disorders, we formed the PGC 
CNV Analysis Group. Our goal was to enable large-scale analyses of CNVs in psychiatry 
using centralized and uniform methodologies for CNV calling, quality control, and 
statistical analysis. Here, we report the largest genome-wide analysis of CNVs for any 
psychiatric disorder to date, using datasets assembled by the Schizophrenia Working 
Group of the PGC.  
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Data processing and meta-analytic methods 
Raw intensity data were obtained from 57,577 subjects from 43 separate 
datasets (Supplementary Table 2). After CNV calling and quality control (QC), 41,321 
subjects were retained for analysis. We developed a centralized pipeline for systematic 
calling of CNVs for Affymetrix and Illumina platforms. (Methods and Supplementary 
Figure 1). The pipeline included multiple CNV callers run in parallel. Data from Illumina 
platforms were processed using PennCNV 15 and iPattern 16. Data from Affymetrix 
platforms were analyzed using PennCNV and Birdsuite 17.Two additional methods, 
iPattern and C-score 18, were applied to data from the Affymetrix 6.0 platform. In order 
to ensure proper normalization of the X chromosome, male and female subjects were 
normalized separately. The CNV calls from each program were converted to a 
standardized format and a consensus call set was constructed by merging CNV outputs 
at the sample level. Only CNV segments that were detected by all algorithms were 
retained. We performed QC at the platform level to exclude samples with poor probe 
intensity and/or an excessive CNV load (number and length). A final set of rare, high 
quality CNVs was defined as those >20kb in length, at least 10 probes, and <1% MAF.  
Genetic associations were investigated by case-control tests of CNV burden at 
four levels: (1) genome-wide (2) pathways, (3) genes, and (4) CNV breakpoints. Analyses 
controlled for SNP-derived principal components, sex, genotyping platform and data 
quality metrics. Multiple-testing thresholds for genome-wide significance were 
estimated from family-wise error rates drawn from permutation 
 
Genome wide analysis of CNV burden 
An elevated burden of rare CNVs among SCZ cases has been well established 2. 
We applied our meta-analytic framework to measure the consistency of overall CNV 
burden across genotyping platforms, and whether a measurable amount of CNV burden 
persists outside of previously implicated CNV regions. Consistent with previous 
estimates, the overall CNV burden was significantly greater among SCZ cases when 
measured as total Kb covered (OR=1.12, p = 5.7x10-15), genes affected (OR=1.21, p = 
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6.6x10-21), or CNV number (OR=1.03, p = 1x10-3). The burden signal above was driven by 
CNVs located within genes. Focusing heretofore on the number of genes affected by 
CNV, the burden metric with the strongest signal of enrichment in our study, the effect 
size was consistent across all genotyping platforms (Figure 1a). When we split by CNV 
type, the effect size for copy number losses (OR=1.40, p = 4x10-16) was greater than for 
gains (OR=1.12, p = 2x10-7) (Supplementary Figures 2 and 3). Partitioning by CNV 
frequency (based on 50% reciprocal overlap with the full call set, Methods), CNV burden 
was enriched among cases across a range of frequencies, up to counts of 80 (MAF = 
0.4%) in the combined sample (Figure 1b). CNV burden results for individual cohorts are 
provided in Supplementary Figure 4. We observed no enrichment in CNV burden when 
considering only variants that did not overlap exons (Supplementary Figure 5) 
A primary question in this study is the contribution of novel loci to the excess 
CNV burden in cases. After removing nine previously implicated CNV loci (where 
reported p-values exceed our designated multiple testing threshold, Supplementary 
Table 1), excess CNV burden in SCZ remained significantly enriched (genes affected 
OR=1.11, p = 1.3x10-7, Figure 1b). CNV burden also remained significantly enriched after 
removal of all reported loci from Supplementary Table 1, but the effect-size was greatly 
reduced (OR = 1.08) compared to the enrichment overall (OR = 1.21). When we 
partitioned CNV burden by frequency, we found that much of the previously 
unexplained signal was restricted to ultra-rare events (i.e., MAF < 0.1%, Figure 1b).  
 
Gene-set (pathway) burden 
We assessed whether CNV burden was concentrated within defined sets of genes 
involved in neurodevelopment or neurological function. A total of 36 gene-sets were 
evaluated (for a description see Supplementary Table 3), consisting of gene-sets 
representing neuronal function, synaptic components and neurological and 
neurodevelopmental phenotypes in human (19 sets), gene-sets based on brain 
expression patterns (7 sets), and human orthologs of mouse genes whose disruption 
causes phenotypic abnormalities, including neurobehavioral and nervous system 
 12 
abnormality (10 sets). Genes not expressed in brain (1 set) or associated with abnormal 
phenotypes in mouse organ systems unrelated to brain (7 sets) were included as 
negative controls. We mapped CNVs to genes if they overlapped by at least one exonic 
basepair.  
Gene-set burden was tested using logistic regression deviance test 6. In addition 
to using the same covariates included in genome-wide burden analysis, we controlled 
for the total number of genes per subject spanned by rare CNVs to account for signal 
that merely reflects the global enrichment of CNV burden in cases 19. Multiple-testing 
correction (Benjamini-Hochberg False Discovery Rate, BH-FDR) was performed 
separately for each gene-set group and CNV type (gains, losses). After multiple test 
correction (Benjamini-Hochberg FDR ≤ 10%) 15 gene-sets were enriched for rare loss 
burden in cases and 4 for rare gains in cases, none of which are negative control sets 
(Figure 2). 
Of the 15 sets significant for losses, the majority consisted of synaptic or other 
neuronal components (9 sets); in particular, “GO synaptic” (GO:0045202) and the 
activity-regulated cytoskeleton-associated protein complex, or “ARC complex”, rank first 
based on statistical significance and effect-size respectively (Figure 2a). Losses in cases 
were also significantly enriched for genes involved in nervous system or behavioral 
phenotypes in mouse but not for gene-sets related to other organ system phenotypes 
(Figure 2c).  To account for dependency between synaptic and neuronal gene-sets, we 
re-tested loss burden following a step-down logistic regression approach, ranking gene-
sets based on significance or effect size (Supplementary Table 4). Only GO synaptic and 
ARC complex were significant in at least one of the two step-down analyses, suggesting 
that burden enrichment in the other neuronal categories is mostly captured by the 
overlap with synaptic genes. Following the same approach, the mouse 
neurological/neurobehavioral phenotype set remained nominally significant, suggesting 
that a portion of this signal was independent of the synaptic gene set. Pathway 
enrichment was less pronounced for duplications, consistent with the smaller burden 
effects for this class of CNV. Among synaptic or other neuronal components, duplication 
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burden was significantly enriched only for NMDA receptor complex; (Figure 2b); none of 
the mouse phenotype sets passed the significance threshold for duplications (Figure 
2d).  
Given that synaptic gene sets were robustly enriched for deletions in cases, and 
with an appreciable contribution from loci that have not been strongly associated with 
SCZ previously, pathway-level interactions of these sets were further investigated. A 
protein-interaction network was seeded using the synaptic and ARC complex genes that 
were intersected by rare deletions in this study (Figure 3). A graph of the network 
highlights multiple subnetworks of synaptic proteins including pre-synaptic adhesion 
molecules (NRXN1, NRXN3), post-synaptic scaffolding proteins (DLG1, DLG2, DLGAP1, 
SHANK1, SHANK2), glutamatergic ionotropic receptors (GRID1, GRID2, GRIN1, GRIA4), 
and complexes such as Dystrophin and its synaptic interacting proteins (DMD, DTNB, 
SNTB1, UTRN).  A subsequent test of the Dystrophin glycoprotein complex (DGC) 
revealed that deletion burden of the synaptic DGC proteins (intersection of “GO DGC” 
GO:0016010 and “GO synapse” GO:0045202) was enriched in cases  (Deviance test P = 
0.05), but deletion burden of the full DGC was not significant (P = 0.69). 
 
Gene CNV association  
To define specific loci that confer risk for SCZ, we tested CNV association at the level of 
individual genes, using logistic regression deviance test and the same covariates 
included in genome-wide burden analysis. To correctly account for large CNVs that 
affect multiple genes, we aggregated adjacent genes into a single locus if their copy 
number was highly correlated across subjects (more than 50% subject overlap). CNVs 
were mapped to genes if they overlapped one or more exons. The criterion for genome-
wide significance used the Family-Wise Error Rate (FWER) < 0.05. The criterion for 
suggestive evidence used a Benjamini-Hochberg False Discovery Rate (BH-FDR) < 0.05.  
Of eighteen independent CNV loci with gene-based BH-FDR < 0.05, two were 
excluded based on CNV calling accuracy or evidence of a batch effect (Supplementary 
Note). The sixteen loci that remain after these additional QC steps, comprising 
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seventeen separate association signals, are listed in Table 1. P-values for this summary 
table were obtained by re-running our statistical model across the entire region 
(Supplementary Note). These sixteen loci represent a set of novel (n=6), previously 
reported (n=4), and previously implicated (n=7) regions, with 22q11.21 comprising two 
separate association signals at the same locus. Manhattan plots of the gene association 
for losses and gains are provided in Figure 4. A permutation-based false discovery rate 
yielded similar estimates to BH-FDR.  
Eight loci attain genome-wide significance, including copy number losses at 
1q21.1, 2p16.3 (NRXN1), 3q29, 15q13.3, 16p11.2 (distal) and 22q11.2 along with gains 
at 7q11.23 and 16p11.2 (proximal). An additional eight loci meet criterion for suggestive 
association, including six that have not been reported previously in association with SCZ. 
Based on our estimation of False Discovery Rates (BH and permutations), we expect to 
observe less than two associations meeting suggestive criteria by chance. In order to 
further evaluate the six new candidate loci identified here, we performed experimental 
validation of CNV calls in a subset of samples by digital droplet PCR (ddPCR, see 
Methods). Validation rates of 100% were obtained for gains of DMRT1, MAGEA11 and 
distal Xq28, losses of VPS13B, and gains and losses of ZNF92 (Supplementary Table 5). 
We obtained a low validation rate at one locus, ZMYM5 (64%), and therefore do not 
consider the association at this locus convincing.  
 
Breakpoint level CNV association  
With our sample size and uniform CNV calling pipeline, many individual CNV loci 
can be tested with adequate power at the CNV breakpoint level (i.e. the SNP probe 
defining the start and end of the CNV segment), potentially facilitating discovery at a 
finer resolution than locus-wide tests. Tests for association were performed at each CNV 
breakpoint using the residuals of case-control status after controlling for analysis 
covariates, with significance determined through permutation. Results for losses and 
gains are shown in Supplementary Figure 6. Four independent CNV loci surpass 
genome-wide significance, all of which were also identified in the gene-based test, 
 15 
including the 15q13.2-13.3 and 22q11.21 deletions, 16p11.2 duplication, and 1q21.1 
deletion and duplication. While these loci represent fewer than half of the previously 
implicated SCZ loci, we do find support for all loci where the association originally 
reported meets the criteria for genome-wide correction in this study. We examined 
association among all previously reported loci showing association to SCZ, including 18 
CNV losses and 25 CNV gains (Supplementary Table 6); 8 loci have BH-FDR q-value < 
0.05, 13 loci have BH-FDR q-value < 0.1, and 25 of the 42 loci were associated with SCZ 
at an uncorrected p < .05.  
Associations at some loci become better delineated through breakpoint-level 
analysis. For instance, NRXN1 at 2p16.3 is a CNV hotspot, and exonic deletions of this 
gene are significantly enriched in SCZ9,20. In this large sample, we observe a high density 
of “non-recurrent” deletion breakpoints in cases and controls. A snapshot of the 
breakpoint association results from the PGC CNV browser (see URLs) reveals a saw-
tooth pattern of association. Predominant peaks correspond to exons and 
transcriptional start sites of NRXN1 isoforms (Figure 5). This example highlights how, 
with high diversity of alleles at a single locus, the association peak may become more 
refined, and in some cases converge toward individual functional elements. Similarly, 
visualization of the previously reported SCZ risk loci on 16p13.2 and 8q11.23 reveals a 
high density of duplication breakpoints, which better delineate genes in these regions. It 
is important, however, to note that CNV breakpoints in the current study are estimated 
from genotyped SNPs around the true breakpoint, and that these breakpoint estimates 
are limited by the resolution of the genotyping platform, and therefore subject to error. 
 
Novel risk alleles are predominantly NAHR-mediated CNVs 
Many CNV loci that have been strongly implicated in human disease are hotspots 
for non-allelic homologous recombination (NAHR), a process which in most cases is 
mediated by flanking segmental duplications 21. We defined a CNV as “NAHR” when 
both the start and end breakpoint is located within a segmental duplication. Consistent 
with the importance of NAHR in generating CNV risk alleles for schizophrenia, most of 
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the loci in Table 1 are flanked by segmental duplications. Moreover, after excluding loci 
that have been implicated in previous studies, the remaining loci with FDR < 0.05 in the 
gene-base burden test were NAHR enriched (6.03-fold, P=0.008; Supplementary Figure 
7), when compared to a null distribution determined by randomizing the genomic 
positions of associated genes (Supplemental Note). These findings suggest that the 
novel SCZ CNVs share similar characteristics to known pathogenic CNVs in that they tend 
to occur in regions prone to high rates of recurrent mutation.  
 
Discussion   
The present study of the PGC SCZ CNV dataset includes the majority of all 
microarray data that has been generated in genetic studies of SCZ to date. In this, we 
find definitive evidence for eight loci, surpassing strict genome-wide multiple testing 
correction. We also find evidence for a contribution of novel CNVs conferring either risk 
or protection to SCZ, with an FDR < 0.05. The complete results, including CNV calls and 
statistical evidence at the gene or breakpoint level, can be viewed using the PGC CNV 
browser (URLs). Our data suggest that the undiscovered novel risk loci that can be 
detected with current genotyping platforms lie at the ultra-rare end of the frequency 
spectrum and still larger samples will be needed to identify them at convincing levels of 
statistical evidence.  
Collectively, the eight SCZ risk loci that surpass genome-wide significance are 
carried by a small fraction (1.4%) of SCZ cases in the PGC sample. We estimate 0.85% of 
the variance in SCZ liability is explained by carrying a CNV risk allele within these loci 
(Supplementary Note). As a comparison, 3.4% of the variance in SCZ liability is explained 
by the 108 genome-wide significant loci identified in the companion PGC GWAS analysis. 
Combined, the CNV and SNP loci that have been identified to date explain a small 
proportion (<5%) of heritability. The large dataset here provides an opportunity to 
evaluate the strength of evidence for a variety of loci where an association with SCZ has 
been reported previously. Of 44 published findings from the recent literature, we find 
evidence for 8 loci at a false discovery rate of 5% and nominal support for an additional 
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17 loci (uncorrected p < 0.05, Supplementary Table 6). Thus, nearly half of the existing 
candidate loci retain some support in our combined analysis. However we also find a 
lack of evidence for many of the previously identified loci, underscoring the value of 
meta-analytic efforts to assess the validity of such reports. A lack of strong evidence in 
this dataset (which includes samples that overlap with many of the previous studies) 
may in some cases simply reflect that statistical power is limited for very rare variants, 
even in large samples. However, it is likely that some of the earlier findings represent 
chance associations; indeed, the loci that are not supported by our data consist largely 
of loci for which the original statistical evidence was weak (Supplementary Table 6). 
Thus, our results help to refine the list of promising candidate CNVs. Continued efforts 
to evaluate the growing number of candidate variants has considerable value for 
directing future research efforts focused on specific loci.  
The novel candidate loci meeting suggestive criteria in this study include two 
regions on chromosome X. It has been hypothesized that sex-linked loci contribute to 
SCZ, based originally on the observation of an increased rate of sex chromosome 
aneuploidy in cases 22. X-linked loci could not be detected in previous CNV studies of 
SCZ, because none to date evaluated variants on the sex chromosomes. In the current 
study, accurate calls were obtained by controlling for sex chromosome ploidy in the 
normalization and variant calling methods. Notably, duplications of distal Xq28 (regional 
P = 3.6x10-4, OR = 8.9, Table 1 and Supplementary Figure 8) appear to confer risk for 
SCZ in both males and females, and the effect size was greatest in males (P = 0.01, OR = 
∞). Similar patterns consistent with dominant X-linked effects were observed at other 
loci (Supplementary Table 7). Duplications of distal Xq28 have been reported in 
association with developmental delay in both sexes 23,24.  Notably, of 26 subjects that 
have been described clinically, nearly half (12/26) have behavioral or psychiatric 
conditions. Of the five reciprocal deletions that were detected in this study, none were 
observed in males, consistent with hemizygous loss of distal Xq28 being associated with 
recessive embryonic lethality in males 24. Thus, mounting evidence indicates that 
increased copy number of distal Xq28 is associated with psychiatric illness. These results 
 18 
also provide a further demonstration that CNV risk factors in schizophrenia overlap with 
loci that contribute to pediatric developmental disorders 1,25. 
We observed multiple “protective” CNVs that showed a suggestive enrichment in 
controls, including duplications of 22q11.2, and MAGEA11 along with deletions and 
duplications of ZNF92. No protective effects were significant after genome-wide 
correction. Moreover, a rare CNV that confers reduced risk for SCZ may not confer a 
general protection from neurodevelopmental disorders. For example, microduplications 
of 22q11.2 appear to confer protection from SCZ 26; however, such duplications have 
been shown to increase risk for developmental delay and a variety of congenital 
anomalies in pediatric clinical populations 27. It is probable that some of the 
undiscovered rare alleles affecting risk for SCZ confer protection but larger sample sizes 
are needed to determine this unequivocally. If it is true that a proportion of CNVs 
observed in our control sample represent rare protective alleles, then the heritability of 
SCZ explained by CNVs may not be fully accounted for by the excess CNV burden in 
cases. 
Our results provide strong evidence that deletions in SCZ are enriched within a 
highly connected network of synaptic proteins, consistent with previous studies 2,6,10,28.  
The large CNV dataset here allows a more detailed view of the synaptic network and 
highlights subsets of genes account for the excess deletion burden in SCZ, including 
synaptic cell adhesion and scaffolding proteins, glutamatergic ionotropic receptors and 
protein complexes such as the ARC complex and DGC. Modest CNV evidence implicating 
Dystrophin (DMD) and its binding partners is intriguing given that the involvement of 
certain components of the DGC have been postulated 29, 30 and disputed 31 previously. 
Larger studies of CNV are needed to define a role for this and other synaptic sub-
networks in SCZ. 
Our current study is well-powered to detect CNVs of large effect that occur in 
>0.1% of cases, but is underpowered to detect association to variants with modest 
effect sizes or to ultra-rare variants regardless of effect size. Furthermore, this study did 
not assess the contribution of common CNVs to SCZ, one instance of which we know: a 
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recent study has demonstrated that the causal variants underlying the strongest 
common variant association in SCZ include duplications of Complement factor 4A 35. 
Lastly, we recognize that a majority of structural variants (SVs) are not detectable with 
current genotyping platforms 32. New technologies for whole genome sequencing will 
ultimately provide an assessment of the contribution of a wider array of rare variants 
including balanced rearrangements, small CNVs 33 and short tandem repeats 34.  
This study represents a milestone. Large-scale collaborations in psychiatric 
genetics have greatly advanced discovery through genome-wide association studies. 
Here we have extended this framework to rare CNVs. Our knowledge of the 
contribution from lower frequency variants gives us confidence that the application of 
this framework to large newly acquired datasets has the potential to further the 
discovery of loci and identification of the relevant genes and functional elements.  
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URLs 
PGC CNV browser, http://pgc.tcag.ca/gb2/gbrowse/pgc_hg18.  
Visualization 16p13.2: http://bit.ly/1NPgIuq 
Visualization of 8q11.23 locus: http://bit.ly/1PwdYTt 
Xq28 gene reviews: http://bit.ly/2au9QGb 
Genetic Cluster Computer (GCC): https://userinfo.surfsara.nl/systems/lisa 
 
Data Availability-  
The PGC CNV resource is now publicly available through a custom browser at 
http://pgc.tcag.ca/gb2/gbrowse/pgc_hg18/ and the rare CNV call set can be obtained 
from the European Genome-Phenome Archive (Study accession #EGAS00001001960).  
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Figure Legends 
 
Figure 1. CNV Burden  
(A) Forest plot of CNV burden (measured here as genes affected by CNV), partitioned by 
genotyping platform, with the full PGC sample at the bottom. CNV burden is calculated 
by combining CNV gains and losses. Numbers of case and controls for each platform are 
listed, and “genes” denotes the mean number of genes affected by a CNV in controls. 
Burden tests use a logistic regression model predicting SCZ case/control status by CNV 
burden along with covariates (see methods). The odds ratio is the exponential of the 
logistic regression coefficient, and odds ratios above one predict increased SCZ risk. (B) 
CNV burden partitioned by CNV frequency. For reference, for autosomal CNVs, a CNV 
count of 41 in the sample corresponds to frequency of 0.1% in the full PGC sample. 
Using the same model as above, each CNV was placed into a single CNV frequency 
category based on a 50% reciprocal overlap with other CNVs. CNV gene burden with 
inclusion of all CNVs are shown in green, and burden excluding previously implicated 
CNV loci are shown in blue. 
 
Figure 2: Gene-set Burden 
Gene-set burden test results for rare losses (a, c) and gains (b, d); frames a-b display 
gene-sets for neuronal function, synaptic components, neurological and 
neurodevelopmental phenotypes in human; frames c-d display gene-sets for human 
homologs of mouse genes implicated in abnormal phenotypes (organized by organ 
systems); both are sorted by –log 10 of the logistic regression deviance test p-value 
multiplied by the beta coefficient sign, obtained for rare losses when including known 
loci. Gene-sets passing the 10% BH-FDR threshold are marked with “*”. Gene-sets 
representing brain expression patterns were omitted from the figure because only a few 
were significant (losses: 1, gains: 3).  
 
Figure 3: Protein Interaction Network for Synaptic Genes 
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Synaptic and ARC-complex genes intersected by a rare loss in at least 4 case or control 
subjects and with genic burden Benjamini-Hochberg FDR <= 25% (red discs) were used 
to query GeneMANIA36 and retrieve additional protein interaction neighbors, resulting 
in a network of 136 synaptic genes. Genes are depicted as disks; disk centers are colored 
based on rare loss frequency (Freq.SZ and Freq.CT) being prevalent in cases or controls; 
disk borders are colored to mark (i) gene implication in human dominant or X-linked 
neurological or neurodevelopmental phenotype, (ii) de novo mutation (DeN) reported 
by Fromer et al. 28, split between LOF (frameshift, stop-gain, core splice site) and 
missense or amino acid insertion / deletion, (iii) implication in mouse neurobehavioral 
abnormality. Pre-synaptic adhesion molecules (NRXN1, NRXN3), post-synaptic scaffolds 
(DLG1, DLG2, DLGAP1, SHANK1, SHANK2) and glutamatergic ionotropic receptors 
(GRID1, GRID2, GRIN1, GRIA4) constitute a highly connected subnetwork with more 
losses in cases than controls. 
 
Figure 4: Gene Based Manhattan Plot.  
Manhattan plot displaying the –log10 deviance p-value for (a) CNV losses and (b) CNV 
gains the gene-based test. P-value cutoffs corresponding to FWER < 0.05 and BH-FDR < 
0.05 are highlighted in red and blue, respectively. Loci significant after multiple test 
correction are labeled.  
 
Figure 5: Manhattan plot of breakpoint-level associations across the Neurexin-1 locus  
The manhattan plot (for deletions) represents empirical P-values at each deletion 
breakpoint. CNV tracks display duplications (blue) and deletions (red) detected in cases 
and controls from the PGC SCZ dataset.  
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Table 1: Significant CNV loci from gene-based association test 
CHR START END locus GENE Status 
Putative 
Mechanism CNV test Direction FWER BH-FDR CAS CON 
Regional 
P-value 
Odds Ratio  
[95% CI] 
22 17,400,000 19,750,000 22q11.21 
Previously 
Implicated NAHR loss risk yes 3.54E-15 64 1 5.70E-18 67.7 [9.3-492.8] 
16 29,560,000 30,110,000 
16p11.2 
(proximal) 
Previously 
Implicated NAHR gain risk yes 5.82E-10 70 7 2.52E-12 9.4 [4.2-20.9] 
2 50,000,992 51,113,178 2p16.3 NRXN1 
Previously 
Implicated NHEJ loss risk yes 3.52E-07 35 3 4.92E-09 14.4 [4.2-46.9] 
15 28,920,000 30,270,000 15q13.3 
Previously 
Implicated NAHR loss risk yes 2.22E-05 28 2 2.13E-07 15.6 [3.7-66.5] 
1 144,646,000 146,176,000 1q21.1 
Previously 
Implicated NAHR loss+gain risk yes 0.00011 60 14 1.50E-06 3.8 [2.1-6.9] 
3 197,230,000 198,840,000 3q29 
Previously 
Implicated NAHR loss risk yes 0.00024 16 0 1.86E-06 INF 
16 28,730,000 28,960,000 16p11.2 (distal) 
Previously 
Reported NAHR loss risk yes 0.0029 11 1 5.52E-05 20.6 [2.6-162.2] 
7 72,380,000 73,780,000 7q11.23 
Previously 
Reported NAHR gain risk yes 0.0048 16 1 1.68E-04 16.1 [3.1-125.7] 
X 153,800,000 154,225,000 Xq28 (distal) Novel NAHR gain risk no 0.049 18 2 3.61E-04 8.9 [2.0-39.9] 
22 17,400,000 19,750,000 22q11.21 
Previously 
Reported NAHR gain protective no 0.024 3 16 4.54E-04 0.15 [0.04-0.52] 
7 64,476,203 64,503,433 7q11.21 ZNF92 Novel NAHR loss+gain protective no 0.033 131 180 6.71E-04 0.66 [0.52-0.84] 
13 19,309,593 19,335,773 
13q12.11 
ZMYM5 Novel NHAR gain protective no 0.024 15 38 7.91E-04 0.36 [0.19-0.67] 
X 148,575,477 148,580,720 Xq28 MAGEA11 Novel NAHR gain protective no 0.044 12 36 1.06E-03 0.35 [0.18-0.68] 
15 20,350,000 20,640,000 15q11.2 
Previously 
Implicated NAHR loss risk no 0.044 98 50 1.34E-03 1.8 [1.2-2.6] 
9 831,690 959,090 9p24.3 DMRT1 Novel NHEJ loss+gain risk no 0.049 13 1 1.35E-03 12.4 [1.6-98.1] 
8 100,094,670 100,958,984 8q22.2 VPS13B Novel NHEJ loss risk no 0.048 7 1 1.74E-03 14.5 [1.7-122.2] 
7 158,145,959 158,664,998 
7p36.3 VIPR2 
WDR60 
Previously 
Reported NAHR loss+gain risk no 0.046 20 6 5.79E-03 3.5 [1.3-9.0] 
All seventeen association signals listed contain at least one gene with Benjamini-Hochberg false discovery rate (BH-FDR) < 0.05 in the gene-based test, with eight containing at least one gene 
surpassing the family-wise error rate (FWER) < 0.05. Genomic positions listed are using hg18 coordinates. For putative CNV mechanisms, non-allelic homologous recombination (NAHR) and non-
homologous end joining (NHEJ) are listed as the likely genomic feature driving CNV formation at each locus. Regional p-values and odds ratios listed are from a regional test at each locus, where 
we combine CNV overlapping the implicated region and run the same test as used for each gene (logistic regression with covariates and deviance test p-value). CNV losses and gains at the 
22q11.21 locus are listed as separate association signals, as CNV losses associate with SCZ risk while CNV gains associate with protection from SCZ. For each association we indicate whether it 
was previously described in the literature (Previously Reported) and if the reported P-value exceeded the multiple testing correction in this study (Previously Implicated). 
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Online Methods 
 
Overview 
We assembled a CNV analysis group with the goal of leveraging the extensive expertise 
within the Psychiatric Genomics Consortium (PGC) to develop a fully automated 
centralized pipeline for consistent and systematic calling of CNVs for both Affymetrix 
and Illumina platforms. An overview of the analysis pipeline is shown in Supplementary 
Figure 1. After an initial data formatting step we constructed batches of samples for 
processing using four different methods, PennCNV, iPattern, C-score (GADA and 
HMMSeg) and Birdsuite for Affymetrix 6.0. For Affymetrix 5.0 data we used Birdsuite 
and PennCNV, for Affymetrix 500 we used PennCNV and C-score, and for all Illumina 
arrays we used PennCNV and iPattern. We then constructed a consensus CNV call 
dataset by merging data at the sample level and further filtered calls to make a final 
dataset Supplementary Table 2. Prior to any filtering, we processed raw genotype calls 
for a total of 57,577 individuals, including 28,684 SCZ cases and 28,893 controls. 
 
Study Sample 
A complete list of datasets that were included in the current study can be found in  
Supplementary Table 2. A more detailed description of the original studies can be found 
in a previous publication1 
 
Copy Number Variant Analysis Pipeline Architecture and Sample Processing 
All aspects of the CNV analysis pipeline were built on the Genetic Cluster Computer 
(GCC) in the Netherlands https://userinfo.surfsara.nl/systems/lisa. 
 
Input Acceptance and Preprocessing: For Affymetrix we used the *.CEL files (all 
converted to the same format) as input, whereas for Illumina we required Genome or 
Beadstudio exported *.txt files with the following values: Sample ID, SNP Name, Chr, 
Position, Allele1 – Forward, Allele2 – Forward, X, Y, B Allele Freq and Log R Ratio.  
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Samples were then partitioned into ‘batches’ to be run through each pipeline. For 
Affymetrix samples we created analysis batches based on the plate ID (if available) or 
genotyping date. Each batch had approximately 200 samples. Each batch included at 
least 50 subjects of each sex. Affymetrix Power Tools (APT - apt-copynumber-workflow) 
was then used to calculate summary statistics about chips analyzed. Gender mismatches 
identified and excluded as were experiments with MAPD > 0.4. For Illumina data, we 
first determined the genome build and converted to hg18 if necessary and created 
analysis batches based on the plate ID or genotyping date.  
  
Composite Pipeline: The composite pipeline comprises CNV callers PennCNV 2, iPattern 3, 
Birdsuite 4 and C-Score 5 organized into component pipelines. We used all four callers 
for Affymetrix 6.0 data and we used PennCNV and C-Score for Affymetrix 500. Probe 
annotation files were preprocessed for each platform. Once the array design files and 
probe annotation files were pre-processed, each individual pipeline component pipeline 
was run in two steps: 1) processing the intensity data by the core pipeline process to 
produce CNV calls, 2) parsing the specific output format of the core pipeline and 
converting the calls to a standard form designed to capture confidence scores, copy 
number states and other information computed by each pipeline 
 
Merging of CNV data and Quality control (QC) filtering is described in detail in the 
supplementary material. Briefly, for each subject CNV calls were made using multiple 
algorithms. Only CNV calls that were made using multiple algorithms were included in 
the call set. Sample level QC filtering was performed by removing arrays with excessive 
probe variance or GC bias and removal of samples with mismatches in gender or 
ethnicity or chromosomal aneuploidies. The final filtered CNV dataset was annotated 
with Refseq genes (transcriptions and exons). After this stage of quality control (QC), we 
had a total of 52,511 individuals, with 27,034 SCZ cases and 25,448 controls. To make 
our final dataset of rare CNVs for all subsequent analysis we filtered out variants that 
were present at >= 1% (50% reciprocal overlap) frequency in cases and controls 
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combined. We included in the call set CNVs that were ≥20 kb and ≥10 probes in length 
and overlapped < 50% with regions tagged as copy number polymorphic on any other 
platform.  
 
In order to minimize the impact of technical artifacts and potential confounds on CNV 
association results, we removed from the dataset individuals that did not pass QC 
filtering from the companion PGC GWAS study of schizophrenia 1 as well as well as case 
or control samples that could not be matched by array platform or reconciled by using a 
common set of probes.  
 
Statistics 
Regression of potential confounds on case-control ascertainment 
The PGC cohorts are a combination of many datasets drawn from the US and Europe, 
and it is important to ensure that any bias in sample ascertainment does not drive 
spurious association to SCZ. In order to ensure the robustness of the analysis, burden 
and gene-set analyses included potential confounding variables as covariates in a logistic 
regression framework. Due to the number of tests run at breakpoint level association, 
we employed a step-wise logistic regression approach to allow for the inclusion of 
covariates in our case-control association, which we term the SCZ residual phenotype. 
Covariates included sex, genotyping platform, and ancestry principal components 
derived from SNP genotypes on the same samples in a previous study1. Control for 
population stratification is described in the supplementary material. We were unable to 
control for dataset or genotyping batch, as a subset of the contributing datasets are fully 
confounded with case/control status. Only principal components that showed a 
significant association to small CNV burden were used (small CNV being defined as 
autosomal CNV burden with CNV < 100 kb in size). Among the top 20 principal 
components, only the 1st, 2nd, 3rd, 4th, and 8th principal component showed association 
with small CNV burden (with p < 0.01 used as the significance cutoff).  
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Lastly, in order to control for case-control differences in CNV ascertainment due to data 
quality we sought to identify data quality metrics that were confounded with case 
status. Affymetrix (MAPD and waviness-sd) and Illumina (LRRSD, BAFSD, GCWF) QC 
metrics were re-examined across studies to assess if any additional outliers were 
present. Only three outliers were removed as their mean B allele (or minor allele) 
frequency deviated significantly from 0.5. Many CNV metrics are auto-correlated, as 
they measure similar patterns of variation in the probe intensity. Thus, we focused on 
the primary measure of probe variance – MAPD and LRRSD.  Among Affymetrix 6.0 
datasets, MAPD did not differ between in cases and controls (t=1.14, p = 0.25). 
However, among non-Affymetrix 6.0 datasets, LRRSD showed significant differences 
between cases and controls (t=-35.3, p < 2e-16), with controls having a higher 
standardized mean LRRSD (0.227) than cases (-0.199).  Thus, to control for any spurious 
associations driven by CNV calling quality, we included MAPD (for Affymetrix platforms) 
or LRRSD (for Illumina platforms) as covariates in downstream analysis, which we 
designate as our “CNV metric” covariate for each individual. Prior to inclusion in the 
combined dataset, the CNV metric variable was normalized within each respective 
genotyping platform. 
 
To calculate the SCZ residual phenotype, we first fit a logistic regression model of 
covariates to affection status, and then extracted the Pearson residual values for use in 
a quantitative association design for downstream analyses. Residual phenotype values 
in cases are all above zero, and controls below zero, and are graphed against overall kb 
burden in Supplementary Figure 9. We removed three individuals with an SCZ residual 
phenotype greater than three (or negative three in controls). After the post-processing 
round of QC, we retained a dataset with a total of 41,321 individuals comprising 21,094 
SCZ cases and 20,227 controls. 
 
CNV burden analysis 
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We analyzed the overall CNV burden in a variety of ways to discern which general 
properties of CNV are contributing to SCZ risk. Overall individual CNV burden was 
measured in 3 distinct ways – 1) Kb burden of CNVs, 2) Number of genes affected by 
CNVs, and 3) Number of CNVs. Genes were counted only if the CNV overlapped a coding 
exon. We also partitioned our analyses by CNV type, size, and frequency. CNV type is 
defined as copy number losses (or deletions), copy number gains (or duplications), and 
both copy number losses and gains. To assign a specific allele frequency to a CNV, we 
used the --cnv-freq-method2 command in PLINK, whereby the frequency is determined 
as the total number of CNV overlapping the target CNV segment by at least 50%. This 
method differs from other methods that assign CNV frequencies by genomic region, 
whereby a single CNV spanning multiple regions may be included in multiple frequency 
categories. 
 
For Figure 1, and Supplementary Figures 2 and 3, we partitioned CNV burden by 
genotyping platform, and the abbreviations for each platform are expanded below: 
 
A500: Affymetrix 500 
I300: Illumina 300K 
I600: Illumina 610K and Illumina 660W 
A5.0: Affymetrix 5.0 
A6.0: Affymetrix 6.0 
omni: OmniExpress and OmniExpress plus Exome 
 
Due to the small sample size of the Omni 2.5 array (28 cases and 10 controls), they were 
excluded from presentation in the figure, but are included in all burden analyses with 
the total PGC sample. Using a logistic regression framework with the inclusion of 
covariates detailed above, we predicted SCZ status using CNV burden as an independent 
predictor variable, thus allowing us to get an accurate estimate of the contribution of 
CNV burden. In addition, to determine the proportion of CNV burden risk that is 
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attributable to loci that have not been implicated in previous studies of SCZ, we ran all 
burden analyses after removing CNVs that overlapped previously implicated CNV 
boundaries by more than 10%.   
CNV breakpoint level association 
Association was tested at each respective CNV breakpoint. Three categories of CNV 
were tested: deletions, duplications, and deletions and duplications combined. All 
analyses were run using PLINK6. 
  
We ran breakpoint level association using the SCZ residual phenotype as a quantitative 
variable, with significance determined through permutation of phenotype residual 
labels. An additional z-scoring correction, explained below, is used to control for any 
extreme values in the SCZ residual phenotype and efficiently estimate two-sided 
empirical p-values for highly significant loci. To ensure against the potential loss of 
power from the inclusion of covariates, we also ran a single degree of freedom Cochran-
Mantel-Haenzel (CMH) test stratified by genotyping platform, with a 2 (CNV carrier 
status) x 2 (phenotype status) x N (genotyping platform) contingency matrix. While the 
CMH test does not account for more subtle biases that could drive false positive signals, 
it is robust to signals driven by a single platform and allows for each CNV carrier to be 
treated equally. Loci the surpassed genome-wide correction in either test was followed 
up for further evaluation. 
 
Z-score recalibration of empirical testing: Breakpoint level association p-values from the 
SCZ residual phenotype were initially obtained by performing one million permutations 
at each CNV position, whereby each permutation shuffles the SCZ residual phenotype 
among all samples, and retains the SCZ residual mean for CNV carriers and non-carriers. 
For extremely rare CNV, however, CNV carriers at the extreme ends of the SCZ residual 
phenotype can produce highly significant p-values. While we understand that such rare 
events are unable to surpass strict genome-wide correction, we wanted to retain all 
tests to help delineate the potential fine-scale architecture within a single region of 
 33 
association. To properly account for the increased variance when only a few individuals 
are tested, we applied an empirical Z-score correction to the CNV carrier mean. In order 
to get an empirical estimate of the variance for each test, we calculated the standard 
deviation of residual phenotype mean differences in CNV carriers and non-carriers from 
5,000 permutations. Z-scores are calculated as the observed case-control mean 
difference divided by the empirical standard deviation, with corresponding p-values 
calculated from the standard normal distribution. Concordance of the initial empirical 
and Z-score p-values are close to unity for association tests with six or more CNV, 
whereas Z-score p-values are more conservative among tests with less than six CNV. 
Furthermore, the Z-score method naturally provides an efficient manner to estimate 
highly significant empirical p-values that would involve hundreds of millions of 
permutations to achieve. Genome-wide correction for multiple testing was determined 
as described in the Supplementary Note 
 
Gene-set burden enrichment analysis: gene-sets 
Gene-sets with an a priori expectation of association to neuropsychiatric disorders were 
compiled and CNV calls were preprocessed as described in the supplementary material.  
 
For each gene-set, we fit the following logistic regression model (as implemented by the 
R function glm of the stats package), where subjects are statistical sampling units: 
y ~ covariates + global + gene-set 
Where: 
 y is the dicotomic outcome variable (schizophrenia = 1, control = 0) 
 covariates is the set of variables used as covariates also in the genome-wide 
burden and breakpoint association analysis (sex, genotyping platform, CNV 
metric, and CNV associated principal components) 
 global is the measure of global genic CNV burden. This covariate accounts for 
non-specific association signal that could be merely reflective of an overall 
difference CNV burden between cases and controls. For the results in the main 
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text, we used the total gene number (abbreviated as U from universe gene-set 
count); we also calculated results for total length (abbreviated as TL) and variant 
number plus variant mean length (abbreviated as CNML) 
 gene-set is the gene-set gene count 
The gene-set burden enrichment was assessed by performing a chi-square deviance test 
(as implemented by the R function anova.glm of the stats package) comparing these 
two regression models: 
y ~ covariates + global 
y ~ covariates + global + gene-set 
We reported the following statistics: 
 coefficient beta estimate (abbreviated as Coeff) 
 t-student distribution-based coefficient significance p-value (as implemented by 
the R function summary.glm of the stats package, abbreviated as Pvalue_glm) 
 deviance test p-value (abbreviated as Pvalue_dev) 
 gene-set size (i.e. number of genes is the gene-set, regardless of CNV data) 
 BH-FDR (Benjamini-Hochberg False Discovery rate) 
 percentage of schizophrenia and control subjects with at least 1 gene, 2 genes, 
etc… impacted by a CNV of the desired type (loss or gain) in the gene-set 
(abbreviated as SZ_g1n, SZ_g2n, … CT_g1n, …) 
Please note that, by performing simple simulation analyses, we realized that Pvalue_glm 
can be extremely over-conservative in presence of very few gene-set counts different 
than 0, while Pvalue_dev tends to be slightly under-conservative. While the two p-
values tend to agree well for gene-set analysis, Pvalue_glm is systematically over-
conservative for gene analysis since smaller counts are typically available for single 
genes. 
 
Gene association analysis 
Subjects were restricted to the ones with at least one rare CNV. Only genes with at least 
a minimum number of subjects impacted by CNV were tested; this threshold was picked 
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by comparing the BH-FDR to the permutation-based FDR and ensuring limited FDR 
inflation (permuted FDR < 1.65 * BH-FDR at BH-FDR threshold = 5%) while maximizing 
power. For gains the threshold was set to 12 counts, while for losses it was set to 8 
counts. 
 
For each gene, we fit the following logistic regression model (as implemented by the R 
function glm of the stats package), where subjects are statistical sampling units: 
y ~ covariates + gene 
Where: 
 y is the dichotomous outcome variable (schizophrenia = 1, control = 0) 
 covariates is the set of variables used as covariates also in the genome-wide 
burden and breakpoint association analysis (sex, genotyping platform, CNV 
metric, and CNV associated principal components) 
 gene is the binary indicator for the subject having or not having a CNV of the 
desired type (loss or gain) mapped to the gene 
The gene burden was assessed by performing a chi-square deviance test (as 
implemented by the R function anova.glm of the stats package) comparing these two 
regression models: 
 y ~ covariates 
 y ~ covariates + gene 
Genome wide correction for multiple testing was determined as described in the 
supplementary material. 
 
Experimental Validation of CNV calls by digital droplet PCR 
For 6 novel candidate loci that were identified in this study, we sought to confirm CNV 
calling accuracy by experimental validation of CNV calls in a subset of study samples. 
Within each association peak we a defined a segment was defined that overlapped a 
majority of calls. Appropriate digital droplet assays were then selected from the BioRad 
catalog. A single FAM-labeled probe was designed for DMRT1, ZMYM5, ZNF92, 
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MAGEA11 and Distal Xq28. Because some deletions of the VPS13B gene were non-
overlapping, two different probes were selected for this locus. CNV calls (up to a 
maximum of 17) were selected from the core target region. Probe details, CNV calls and 
validation results can be found in Supplementary Table 5. Study samples were then 
obtained from two studies (Sweden and CLOZUK) and 4 population control samples 
were obtained from Coriell Cell repositories (ND00745, ND01936, ND00689, ND01317) 
to be used as negative controls for ddPCR assays. EcoRI digested samples (10 ng of 
genomic DNA) were analyzed in triplicate by ddPCR using the Fam-labeled CNV probe 
and HEX-labeled reference probe M0005 RPP30-HEX (Supplementary Table 5) in the 
UCSD CFAR Genomics & Sequencing Core. PCR droplets were generated using a Bio-Rad 
QX100 Droplet Generator, then quantitative PCR was performed using the GeneAmp 
PCR system 9700 (Applied Biosystems) instrument according to manufacturer’s 
protocols (40 cycles at 94°C for 30 sec and 60°C for 1 min). PCR droplets were read & 
analyzed on Bio-Rad QX100 Droplet Reader with QuantaSoft software. 
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